Steroid sulphatase inhibitors for breast cancer therapy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 423-432

  Purohit, A ^a   Woo, L W L ^b   Chander, S K ^a   Newman, S P ^a   Ireson, C ^a   Ho, Y ^a   Grasso, A ^a   Leese, M P ^b   Potter, B V L ^b   Reed, M J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

Aromatase; Breast cancer; Steroid sulphatase (STS); Sulphatase inhibitors

Indexed keywords

2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL BIS SULFAMATE; ANASTROZOLE; ANDROGEN; ANDROSTANEDIOL; ANDROSTENEDIOL; ANGIOGENESIS INHIBITOR; AROMATASE; AROMATASE INHIBITOR; CARBONATE DEHYDRATASE II; COUMARIN DERIVATIVE; COUMATE 667; ESTER; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; PHENOL DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PRASTERONE; PRASTERONE SULFATE; PROTEIN INHIBITOR; STEROID; STERYL SULFATASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOSE TISSUE; ANGIOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG INACTIVATION; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG RESPONSE; DRUG SYNTHESIS; ENZYME ACTIVITY; ERYTHROCYTE; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; FIRST PASS EFFECT; HORMONE SENSITIVITY; HUMAN; HYDROLYSIS; IC 50; LIVER; LOW DRUG DOSE; MOLECULAR BIOLOGY; NONHUMAN; PHARMACOPHORE; POSTMENOPAUSE; PROGNOSIS; REGULATORY MECHANISM; STROMA CELL;

EID: 10744224981     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00353-4     Document Type: Conference Paper

References (60)

1. Woo L.W.L., Howarth N.M., Purohit A., Hejaz H.A.M., Reed M.J., Potter B.V.L. Steroidal and non-steroidal sulphamates as potent inhibitors of steroid sulphatase. J. Med. Chem. 41:1998;1068-1083.
2. Hoffmann R., Rot A., Niiyama S., Billich A. Steroid sulphatase in the human hair follicle concentrates in the dermal papilla. J. Invest. Dermatol. 117:2001;1342-1348.
3. Suitters A.J., Shaw S., Wales M.R., Porter J.R., Leonard J., Woodger R., Brand H., Bodmer M., Foulkes R. Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulphatase. Immunolgy. 91:1997;314-321.
4. Reed M.J., Owen A.M., Lai L.C., Coldham N.G., Ghilchik M.W., Shaikh N.A., James V.H.T. In situ oestrone synthesis in normal breast and breast tumour tissue: effect of treatment with 4-hydroxyandrostenedione. Int. J. Cancer. 44:1989;233-237.
5. Singh A., Purohit A., Duncan L.J., Mokbel K., Ghilchik M.W., Reed M.J. Control of aromatase in breast tumours: the role of the immune system. J. Steroid Biochem. Mol. Biol. 61:1997;185-192.
6. Sasano H., Nagura H., Harada N., Goukon Y., Kimura M. Immunolocalisation of aromatase and other steroidogenic enzymes in human breast disorders. Hum. Pathol. 25:1994;530-535.
7. Esteban J.M., Warsi Z., Haniu M., Hall P., Shively J.E., Chen S. Detection of intratumoral aromatase in breast carcinomas. Am. J. Pathol. 140:1992;337-343.
8. Reed M.J., Lai L.C., Owen A.M., Singh A., Coldham N.G., Purohit A., Ghilchik M.W., Shaikh N.A., James V.H.T. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in post-menopausal women with breast cancer. Cancer Res. 50:1990;193-196.
9. Dowsett M., Goss P.E., Powles T.J., Hutchinson G., Brodie A.M.H., Jeffcoate S.L., Coombes R.C. Use of aromatase inhibitor 4-hydroxy androstenedione in post-menopausal breast cancer: optimisation of therapeutic dose and route. Cancer Res. 47:1987;1957-1961.
10. Dowsett M., Cunningham D.C., Stein R.C., Evans S., Dehennin L., Hedley A., Coombes R.C. Dose-related endocrine effects and pharmocokinetics of oral and intramuscular 4-hydroxy-androstenedione in post-menopausal breast cancer patients. Cancer Res. 49:1989;1306-13012.
11. Dowsett M., Jones A., Johnston S.R.D., Jacobs S., Trunet P., Smith I.E. In vivo measurements of aromatase inhibition by letrozole (CG5 20267) in post-menopausal patients with breast cancer. Clin. Cancer Res. 1:1995;1511-1515.
12. Buzdar A., Donma J., Davidson N., Elledge R., Morgan M., Smith R., Porter L., Nabholtz J., Xiang X., Brady C. Phase III, multicenter, double-blind, randomised study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19:2001;3357-3366.
13. Bajetta E., Zilembo N., Bichisao E., Martinetti A., Buzzoni R., Pozzi P., Bidoli P., Ferrari L., Celio L. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann. Oncol. 11:2000;1017-1022.
14. Hobkirk R. Steroid sulfation. Trends Endocrinol. Metab. 4:1993;69-74.
15. Strott C.A. Steroid sulfotransferases. Endocrinol. Rev. 17:1996;670-697.
16. Noel C.T., Reed M.J., Jacobs H.S., James V.H.T. The plasma concentration of oestrone sulphate in post-menopausal women: lack of diurnal variation, effect of ovariectomy, age and weight. J. Steroid Biochem. 14:1981;1101-1105.
17. Pasqualini J.R., Gelly C., Nguyen B.-L., Vella S. Importance of oestrogen sulphates in breast cancer. J. Steroid Biochem. 34:1989;155-163.
18. Ruder H.J., Loriaux D.L., Lipsett M.B. Estrone sulfate: production rate and metabolism in man. J. Clin. Invest. 51:1972;1020-1023.
19. Reed M.J., Purohit A., Woo L.W.L., Potter B.V.L. The development of steroid sulphatase inhibitors. Endocrinol. Relat. Cancer. 3:1996;9-23.
20. James V.H.T., McNeill J.M., Lai L.C., Newton C.J., Ghilchik M.W., Reed M.J. Aromatase activity in normal breast and breast tumor tissue: in vivo and in vitro studies. Steroids. 50:1987;269-279.
21. Santner S.J., Feil R.D., Santen R.J. In situ estrogen production via estrone sulphatase pathway in breast tumors: relative importance versus aromatase pathway. J. Clin. Endocrinol. Metab. 54:1984;29-33.
22. Utsumi T., Yoshimura N., Takenchi S., Maruta M., Maeda K., Harada N. Elevated steroid sulphatase expression in breast cancer. J. Steroid Biochem. Mol. Biol. 73:2000;141-145.
23. Utsumi T., Yoshimura N., Takenchi S., Ando J., Maruta M., Maeda K., Harada N. Steroid sulphatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 59:1999;377-381.
24. Bonney R.C., Scanlon M.J., Jones D.L., Beranek P.A., Reed M.J., James V.H.T. The inter-relationship between plasma 5-ene adrenal androgens in normal women. J. Steroid Biochem. 20:1984;1353-1355.
25. Poulin R., Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta-5-steroids in ZR-75-1 human breast cancer cell line. Cancer Res. 46:1986;4933-4937.
26. Dauvois S., Labrie F. Androstenedione and androst-5-ene-3β, 17β-diol stimulate DMBA-induced mammary tumors - role of aromatase. Breast Cancer Res. Treat. 13:1989;61-69.
27. J. Poortman, R. Andriesse, A. Agema, G.H. Donker, F. Schwarz, J.H.H. Thijssen, Adrenal androgen secretion and metabolism in post-menopausal women, in: A.R. Genazzani, J.H.H. Thijssen, P.K. Siiteri (Eds.), Adrenal Androgens, Raven Press, New York, 1980, pp. 219-240.
28. Purohit A., Dauvois S., Parker M.G., Potter B.V.L., Williams G.J., Reed M.J. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. J. Steroid Biochem. Mol. Biol. 50:1994;101-104.
29. Billich A., Nussbaumer P., Lehr P. Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal steroid sulphatase inhibitors. J. Steroid Biochem. Mol. Biol. 73:2000;225-235.
30. Morris K.T., Toth-Fejel S., Schmidt J., Fletcher W.S., Pommier R.F. High dehydroepiandrosterone sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery. 130:2001;947-953.
31. Falany J.L., Macrina N., Falany C.N. Regulation of MCF-7 breast cancer cell growth by β-estradiol sulfation. Breast Cancer Res. Treat. 74:2002;167-176.
32. Hobkirk R. Steroid sulfotransferases and steroid sulfate sulphatase: characteristics and biological roles. Can. J. Biochem. Cell Biol. 63:1985;1127-1144.
33. Evans T.R.J., Rowlands M.G., Jarman M., Coombes R.C. Inhibition of oestrone sulphatase enzyme in human placenta and human breast carcinoma. J. Steroid Biochem. Mol. Biol. 39:1991;493-499.
34. Birnbock H., von Angerer E. Sulphate derivatives of 2-phenyl-indoles as novel steroid sulphatase inhibitors. Biochem. Pharmacol. 39:1990;1709-1713.
35. Duncan L.J., Purohit A., Howarth N.M., Potter B.V.L., Reed M.J. Inhibition of oestrone sulphatase activity by estrone-3-O-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res. 53:1993;298-303.
36. Howarth N.M., Purohit A., Reed M.J., Potter B.V.L. Estrone sulphamates: potent inhibitors of estrone sulphatase with therapeutic potential. J. Med. Chem. 37:1994;219-222.
37. Purohit A., Reed M.J., Morris N.C., Williams G.J., Potter B.V.L. Regulation of inhibition of steroid sulphatase activity in breast cancer. Ann. N. Y. Acad. Sci. 784:1996;40-49.
38. Purohit A., Williams C.J., Howarth N.M., Potter B.V.L., Reed M.J. Inactivation of steroid sulphatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Biochemistry. 34:1995;11508-11514.
39. Purohit A., Williams G.J., Roberts C.J., Potter B.V.L., Reed M.J. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int. J. Cancer. 62:1995;106-111.
40. Elger W., Schwarz S., Hadden A., Reddersen G., Schneider B. Sulphamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 55:1995;395-403.
41. Li P.K., Milano S., Kluth L., Rhodes M.E. Synthesis and sulphatase inhibiting properties of non-steroidal estrone sulphatase inhibitors. J. Steroid Biochem. Mol. Biol. 59:1996;41-48.
42. Purohit A., Vernon K.A., Wagenaar-Humelinck A.E., Woo L.W.L., Hejaz H.A.M., Potter B.V.L., Reed M.J. The development of A-ring modified analogues of oestrone-3-O-sulphamate as steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. 64:1998;269-275.
43. Li P.K., Chu G.-H., Peters A., Selcer K.W. Development of potent non-estrogenic estrone sulphatase inhibitors. Steroids. 63:1998;423-432.
44. Purohit A., Woo L.W.L., Singh A., Winterborn C.J., Potter B.V.L., Reed M.J. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a non-steroidal, non-estrogenic steroid sulphatase inhibitor. Cancer Res. 59:1996;4950-4955.
45. Purohit A., Woo L.W.L., Potter B.V.L., Reed M.J. In vivo inhibition of estrone sulphatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res. 60:2000;3394-3396.
46. Purohit A., Woo L.W.L., Barrow D., Hejaz H.A.M., Nicholson R., Potter B.V.L., Reed M.J. Steroidal and non-steroidal sulphamates: new drugs of cancer therapy. Mol. Cell. Endocrinol. 171:2001;129-135.
47. Purohit A., Froome V.A., Wang D.Y., Potter B.V.L., Reed M.J. Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate. J. Steroid Biochem. Mol. Biol. 62:1997;45-51.
48. Elger W., Palme H.-J., Schwarz S. Novel oestrogen sulphamates: a new approach to oral hormone therapy. Exp. Opin. Invest. Drugs. 7:1998;575-589.
49. Ho Y.T., Purohit A., Vicker N., Newman S.P., Robinson J.J., Leese M.P., Ganeshapillai D., Potter B.V.L., Reed M.J. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem. Biophys. Res. Comm. 305:2003;909-914.
50. Armstrong J.M., Myers D.V., Verpoorte J.A., Edsall J.T. Purification and properties of human erthyrocyte carbonic anhydrases. J. Biol. Chem. 241:1966;5137-5149.
51. Parkkila S., Rajaniemi H., Parkkila A.-K., Kivela J., Waheed A., Pastorekova S., Pastorek J., Sly W.S. Carbonic anhydrase inhibitor suppresses the invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 97:2000;2220-2224.
52. Teicher B.A., Liu S.-D., Liu J.-T., Holden S.A., Herman T.S. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 13:1993;1549-1556.
53. Purohit A., Hejaz H.A.M., Woo L.W.L., van Strien A.E., Potter B.V.L., Reed M.J. Recent advances in the development of steroid sulphatase inhibitors. J. Steroid Biochem. Mol. Biol. 69:1999;227-2238.
54. Boivin R.P., Luu-The V., Lachance R., Poirier D. Structure-activity relationships of 17α-derivatives of estradiol as inhibitors of steroid sulphatase. J. Med. Chem. 43:2000;4465-4478.
55. MacCarthy-Morrogh L., Townsend P.A., Purohit A., Hejaz H.A.M., Potter B.V.L., Reed M.J., Packham G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis and microtubule assembly in human breast cancer cells. Cancer Res. 60:2001;5441-5450.
56. M.J. Reed, S.P. Newman, A. Purohit, B. Malini, M.P. Leese, B. LeBlond, D. Bennetto, L.W.L. Woo, B.V.L. Potter, 2-Methoxyestradiol sulfamates are potent anti-cancer agents. Proc AACR (2002) Abstr. 901.
57. Kellis J.T., Vickery L.E. Inhibition of human estrogen synthase (aromatase) by flavones. Science. 255:1984;1032-1034.
58. Campbell D.R., Kurser M.S. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J. Steroid Biochem. Mol. Biol. 46:1993;381-388.
59. Longcope C., Bourget C., Flood C. The production and aromatisation of DHEA in post-menopausal women. Maturitas. 4:1982;325-332.
60. Raobaikady B., Purohit A., Chander S.K., Woo L.W.L., Leese M.P., Potter B.V.L., Reed M.J. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. 84:2003;351-358.